Coadministration of the Heat Shock Protein 90 Antagonist 17-Allylamino-17-demethoxygeldanamycin with Suberoylanilide Hydroxamic Acid or Sodium Butyrate Synergistically Induces Apoptosis in Human Leukemia Cells

Cancer Research

Volumn 63, Issue 23, 2003, Pages 8420-8427

  Rahmani, Mohamed ^a   Yu, Chunrong ^a   Dai, Yun ^a   Reese, Erin ^a   Ahmed, Wesam ^a   Dent, Paul ^a   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; BUTYRIC ACID; CASPASE 3; CASPASE 8; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOCHROME C; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 ANTAGONIST; HISTONE DEACETYLASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN BCL 2; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN P21; PROTEIN P27; RAF PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VORINOSTAT;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROTECTION; CELL STRAIN U937; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZOQUINONES; BUTYRATES; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HL-60 CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYDROXAMIC ACIDS; JURKAT CELLS; LACTAMS, MACROCYCLIC; RIFABUTIN; U937 CELLS;

EID: 0345734267     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Richter, K., and Buchner, J. Hsp90: chaperoning signal transduction. J. Cell. Physiol., 188: 281-290, 2001.
2. Garrido, C., Gurbuxani, S., Ravagnan, L., and Kroemer, G. Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem. Biophys. Res. Commun., 286: 433-442, 2001.
3. Schneider, C., Sepp-Lorenzino, L., Nimmesgem, E., Ouerfelli, O., Danishefsky, S., Rosen, N., and Hartl, F. U. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc. Natl. Acad. Sci. USA. 93: 14536-14541, 1996.
4. Young, J. C., Moarefi, I., and Hartl, F. U. Hsp90: a specialized but essential protein-folding tool. J. Cell Biol., 154: 267-273, 2001.
5. Stancato, L. F., Silverstein, A. M., Owens-Grillo, J. K., Chow, Y. H., Jove, R., and Pratt, W. B. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. J. Biol. Chem., 272: 4013-4020, 1997.
6. Nimmanapalli, R., O'Bryan, E., and Bhalla, K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res., 61: 1799-1804, 2001.
7. 1 arrest. Cancer Res., 60: 3940-3946, 2000.
8. Kim, H. R., Lee, C. H., Choi, Y. H., Kang, H. S., and Kim, H. D. Geldanamycin induces cell cycle arrest in K562 erythroleukemic cells. IUBMB Life, 48: 425-428, 1999.
9. Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., and Neckers, L. M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA, 91: 8324-8328, 1994.
10. Schulte, T. W., and Neckers, L. M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol., 42: 273-279, 1998.
11. Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., and Pavletich, N. P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell, 89: 239-250, 1997.
12. Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., and Pearl, L. H. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell, 90: 65-75, 1997.
13. Solit, D. B., Zheng, F. F., Drobnjak, M., Munster, P. N., Higgins, B., Verbel, D., Heller, G., Tong, W., Cordon-Cardo, C., Agus, D. B., Scher, H. I., and Rosen, N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res., 8: 986-993, 2002.
14. Kelland, L. R., Sharp, S. Y., Rogers, P. M., Myers, T. G., and Workman, P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. (Bethesda), 91: 1940-1949, 1999.
15. Dunn, F. B. Heat shock protein inhibitor shows antitumor activity. J. Natl. Cancer Inst. (Bethesda), 94: 1194-1195, 2002.
16. Munster, P. N., Basso, A., Solit, D., Norton, L., and Rosen, N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependedent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin. Cancer Res., 7: 2155-2158, 2001. Clin. Cancer Res. 7: 2228-2236, 2001.
17. Munster, P. N., Basso, A., Solit, D., Norton, L., and Rosen, N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependedent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin. Cancer Res., 7: 2155-2158, 2001. Clin. Cancer Res. 7: 2228-2236, 2001.
18. Nimmanapalli, R., O'Bryan, E., Huang, M., Bali, P., Burnette, P. K., Loughran, T., Tepperberg, J., Jove, R., and Bhalla, K. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res., 62: 5761-5769, 2002.
19. Yoshida, M., Horinouchi, S., and Beppu, T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays, 17: 423-430, 1995.
20. Gregory, P. D., Wagner, K., and Horz, W. Histone acetylation and chromatin remodeling. Exp. Cell Res., 265: 195-202, 2001.
21. Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature (Lond.), 389: 349-352, 1997.
22. Van Lint, C., Emiliani, S., and Verdin, E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr., 5: 245-253, 1996.
23. Marks, P. A., Richon, V. M., and Rifkind, R. A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. (Bethesda), 92: 1210-1216, 2000.
24. Richon, V. M., Sandhofr, T. W., Rifkind, R. A., and Marks, P. A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA, 97: 10014-10019, 2000.
25. Ruefli, A. A., Ausserlechner, M. J., Bernhard, D., Sutton, V. R., Tainton, K. M., Kofler, R., Smyth, M. J., and Johnstone, R. W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. USA, 98: 10833-10838, 2001.
26. Rosato, R. R., Wang, Z., Gopalkrishnan, R. V., Fisher, P. B., and Grant, S. Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/mDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int. J. Oncol., 19: 181-191, 2001.
27. Rosato, R. R., Almenara, J. A., Cartee, L., Betts, V., Chellappan, S. P., and Grant, S. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Mol. Cancer Ther., 1: 253-266, 2002.
28. Gore, S. D., and Carducci, M. A. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin. Investig. Drugs, 9: 2923-2934, 2000.
29. Vrana, J. A., Decker, R. H., Johnson, C. R., Wang, Z., Jarvis, W. D., Richon, V. M., Ehinger, M., Fisher, P. B., and Grant, S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene, 18: 7016-7025, 1999.
30. Jung, M. Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem., 8: 1505-1511, 2001.
31. Piekarz, R. L., Robey, R., Sandor, V., Bakke, S., Wilson, W. H., Dahmoush, L., Kingma, D. M., Turner, M. L., Altemus, R., and Bates, S. E. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood, 98: 2865-2868, 2001.
32. Sundstrom, C., and Nilsson, K. Establishment and characterization of a human histioeytic lymphoma cell line (U-937). Int. J. Cancer, 17: 565-577, 1976.
33. Collins, S. J., Gallo, R. C., and Gallagher, R. E. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature (Lond.), 270: 347-349, 1977.
34. Gillis, S., and Watson, J. Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line. J. Exp. Med., 152: 1709-1719, 1980.
35. CIP1/WAF1 induction rather than AKT inhibition. Oncogene. 22: 6231-6242, 2003.
36. Yu, C., Krystal, G., Varticovksi, L., McKinstry, R., Rahmani, M., Dent, P., and Grant, S. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res., 62: 188-199, 2002.
37. Rahmani, M., Dai, Y., and Grant, S. The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-α-mediated process. Exp. Cell Res., 277: 31-47, 2002.
38. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
39. Kirsch, D. G., Doseff, A., Chau, B. N., Lim, D. S., Souza-Pinto, N. C., Hansford, R., Kastan, M. B., Lazebnik, Y. A., and Hardwick, J. M. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J. Biol. Chem., 274: 21155-21161, 1999.
40. Lee, J. T., Jr., and McCubrey, J. A. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia (Baltimore), 16: 486-507, 2002.
41. Basso, A. D., Solit, D. B., Munster, P. N., and Rosen, N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene, 21: 1159-1166, 2002.
42. Sambucetti, L. C., Fischer, D. D., Zabludoff, S., Kwon, P. O., Chamberlin, H., Trogani, N., Xu, H., and Cohen, D. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem., 274: 34940-34947, 1999.
43. Huang, L., and Pardee, A. B. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol. Med., 6: 849-866, 2000.
44. Kelly, W. K., O'Connor. O. A., and Marks, P. A. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Investig. Drugs, 11: 1695-1713, 2002.
45. Yu, X., Guo, Z. S., Marcu, M. G., Neckers, L., Nguyen, D. M., Chen, G. A., and Schrump, D. S. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. (Bethesda), 94: 504-513, 2002.
46. Nimmanapalli, R., Fuino, L., Bali, P., Gasparetto, M., Glozak, M., Tao, J., Moscinski, L., Smith, C., Wu, J., Jove, R., Atadja, P., and Bhalla, K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res., 63: 5126-5135, 2003.
47. Huang, H. C., Liu, Y. C., Liu, S. H., Tzang, B. S., and Lee, W. C. Geldanamycin inhibits trichostatin A-induced cell death and histone H4 hyperacetylation in COS-7 cells. Life Sci., 70: 1763-1775, 2002.
48. Liu, Y., Martindale, J. L., Gorospe, M., and Holbrook, N. J. Regulation of p21WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res., 56: 31-35, 1996.
49. Burgess, A. J., Pavey, S., Warrener, R., Hunter, L. J., Piva, T. J., Musgrove, E. A., Saunders, N., Parsons, P. G., and Gabrielli, B. G. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol. Pharmacol., 60: 828-837, 2001.
50. Suzuki, A., Tsutomi, Y., Akahane, K., Araki, T., and Miura, M. Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene, 17: 931-939, 1998.
51. Wang, Q., Li, N., Wang, X., Kim, M. M., and Evers, B. M. Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3′-kinase inhibition in the KM20 human colon cancer cell line. Clin. Cancer Res., 8: 1940-1947, 2002.
52. Eymin, B., Haugg, M., Droin, N., Sordet, O., Dimanche-Boitrel, M. T., and Solary, E. p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene, 18: 1411-1418, 1999.
53. Moulding, D. A., Giles, R. V., Spiller, D. G., White, M. R., Tidd, D. M., and Edwards, S. W. Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells. Blood, 96: 1756-1763, 2000.
54. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., and Greenberg, M. E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (Wash. DC), 270: 1326-1331, 1995.
55. Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med., 8: S55-S61, 2002.
56. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Pomatico, G., De Placido, S., Bianco, A. R., and Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res., 6: 2053-2063, 2000.
57. Kano, Y., Akutsu, M., Tsunoda, S., Mano, H., Sato, Y., Hooma, Y., and Furukawa, Y. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood, 97: 1999-2007, 2001.
58. L. J. Pharmacol. Exp. Ther., 301: 568-577, 2002.
59. Wang, S., Wang, Z., Boise, L. H., Dent, P., and Grant, S. Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL. Leukemia (Baltimore), 13: 1564-1573, 1999.
60. Bible, K. C., and Kaufmann, S. H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res., 57: 3375-3380, 1997.
61. Wilson, W. H., Sorbara, L., Figg, W. D., Mont, E. K., Sausville, E., Warren, K. E., Balis, F. M., Bauer, K., Raffeld, M., Senderowicz, A. M., and Monks, A. Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm. Clin. Cancer Res., 6: 415-421, 2000.
62. Harvey, S., Decker, R., Dai, Y., Schaefer. G., Tang, L., Kramer, L., Dent, P., and Grant, S. Interactions between 2-fluoroadenine 9-β-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells. Clin. Cancer Res., 7: 320-330, 2001.
63. Nguyen, D. M., Lorang, D., Chen, G. A., Stewart, J. H., Tabibi, E., and Schrump, D. S. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann. Thorac. Surg., 72: 371-378, 2001.
64. Dai, Y., Yu, C., Singh, V., Tang, L., Wang, Z., McInistry, R., Dent, P., and Grant, S. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res., 61: 5106-5115, 2001.
65. Yu, C., Krystal, G., Dent, P., and Grant, S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin. Cancer Res., 8: 2976-2984. 2002.
66. Klejman, A., Rushen, L., Morrione, A., Slupianek, A., and Skorski, T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene, 21: 5868-5876, 2002.
67. Nahta, R., Iglehart, J. D., Kempkes, B., and Schmidt, E. V. Rate-limiting effects of cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res., 62: 2267-2271, 2002.
68. Marks, P. A., Richon, V. M., Breslow, R., and Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol., 13: 477-483, 2001.